Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Science Matters: CD47 Pathway Links To CV Disease, New Drug Development Opportunities

Executive Summary

Initial research about inhibiting CD47 signaling on tumor cells has meant a focus on oncology drug development. New research shows that inhibiting this cell surface molecule could be used to treat atherosclerosis.

You may also be interested in...



Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition

Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.

Forty Seven Raises $75 Million For Possible 'Universal' Cancer Therapy

Forty Seven Inc. spun out of Stanford with a $75 million Series A and an immuno-oncology development program that's already in the clinic with data expected later this year.

Science Matters: Harnessing The Inherent Power Of MAIT Cells

Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC097196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel